Clinical DevelopmentThe first patient was dosed in an expansion cohort with KB-0742, targeting a tumor type sensitive to CDK9 inhibition.
Cost ManagementR&D and SG&A expenses came in lower than prior estimates, indicating better cost management.
Financial PositionKronos ended 2Q24 with $136.6M in cash, cash equivalents, and marketable securities, providing an operational runway.